Here are the 10-Q quarterly reports from AIM ImmunoTech Inc (AIMI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMI filings page.
AIM ImmunoTech reported a first-quarter 2026 net loss of $3.0M on minimal revenues of $22K, reflecting its development-stage status. Operating expenses fell sharply to $2.2M from $3.6M a year earlier, mainly from lower research and general and administrative costs.
Cash and cash equivalents increased to $5.8M at March 31, 2026 from $3.0M at year-end 2025, helped by equity sales, warrant exercises and a $1.8M Series G preferred stock rights offering. Stockholders’ equity improved from a deficit of $(9.8)M to positive equity of $2.1M, aided by an $8.7M reclassification of Class E and F warrants from liability to equity.
The company still faces significant risk: management notes substantial doubt about its ability to continue as a going concern, with working capital constraints, ongoing losses and stockholders’ equity of $2.1M versus the $6M minimum required to maintain NYSE American listing. It relies on additional financings, including Streeterville promissory notes and at-the-market equity sales, while advancing Ampligen for late-stage pancreatic cancer through the DURIPANC Phase 2 study and planning a Phase 3 trial with Thermo Fisher Scientific’s PPD unit.
AIM ImmunoTech Inc. reported another loss-making quarter while facing serious financial pressures and exchange-listing risks. For the three months ended September 30, 2025, revenue from clinical treatment programs was only $26,000, against operating expenses of $2.5 million, leading to an operating loss of $2.4 million and a net loss of $3.3 million. For the first nine months of 2025, the company recorded a net loss of $9.8 million, compared with $11.4 million a year earlier. Cash and cash equivalents were $2.3 million, while total assets were $5.5 million and total liabilities $11.6 million, resulting in a stockholders’ deficit of $6.1 million. A new warrant liability of $7.3 million was recorded after an August 2025 equity and warrant financing. Management states that recurring losses, a working capital deficit and sub-minimum equity raise substantial doubt about the company’s ability to continue as a going concern. AIM executed a 1-for-100 reverse stock split in June 2025 to address low trading prices, and its stock was reinstated on NYSE American, but it must lift stockholders’ equity to at least $6.0 million by June 11, 2026 to remain in compliance.